← SynDRA
TAK-285
SynDRA canonical compound SYN0025688 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | ERBB2 |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- EGFR INHIBITOR
- ERBB2 INHIBITOR
- Receptor protein-tyrosine kinase erbB-2 inhibitor
- Epidermal growth factor receptor erbB1 inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- PAK2
- PFKP
- PEBP1
- PDXK
- PDGFRB
- PDGFRA
- PAK4
- PAICS
- PHKG2
- OPA1
- NUAK2
- NTRK1
- NR2C2
- NQO2
- NLK
- PGRMC1
- PIM1
- NEK7
- PRKACA
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKAA1
- PIP4K2C
- PLK4
- PLK1
- PKN3
- PKN2
- PKN1
- PKMYT1
- NEK9
- NEK3
- PRKCD
- MAPK11
- MAPK9
- MAPK8
Cross-references
Synonyms
- Tak285
- TAK 285
- TAK285
- UNII-70CCB438L6
- N-(2-(4-(3-CHLORO-4-(3-(TRIFLUOROMETHYL)PHENOXY)PHENYLAMINO)-5H-PYRROLO[3,2-D]PYRIMIDIN-5-YL)ETHYL)-3-HYDROXY-3-METHYLBUTANAMIDE
- CHEMBL1614725
- 70CCB438L6
- N-{2-[4-({3-Chloro-4-[3-(Trifluoromethyl)phenoxy]phenyl}amino)-5h-Pyrrolo[3,2-D]pyrimidin-5-Yl]ethyl}-3-Hydroxy-3-Methylbutanamide
- n-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5h-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide
- C26H25ClF3N5O3
- RefChem:187187
- DTXCID10158627
- EGFR/HER2 Kinase Inhibitor TAK-285
- MFCD22124520
- 3poz
- 3rcd
- 3w2o
- MLS006011276
- SCHEMBL982278
- orb1301128
- SCHEMBL29355721
- TAK 285 [WHO-DD]
- EX-A088
- GLXC-90459
- HMS3656J08
- HMS3750E17
- BDBM50358430
- NSC800938
- s2784
- AKOS026674251
- CCG-269993
- CS-0774
- NSC-800938
- SB19365
- SDCCGSBI-0654472.P001
- NCGC00346699-01
- NCGC00346699-06
- NCGC00346699-07
Look up TAK-285 in the interactive SynDRA portal →